INS and diabetes mellitus: Despite advancements in insulin formulation, delivery devices and glucose monitoring, most patients with Type 1 (T1D) and Type 2 (T2D) diabetes remain dependent on exogenous insulin or small-molecule drugs that treat symptoms rather than the underlying cellular and genetic dysregulations [2].